Erik van Zandbergen
Erik van Zandbergen
Chief Operating Officer
Erik joined Julius Clinical in January 2019. His primary drive is to get new therapies to patients through impeccable service delivery to clients.
Related
ESC 2026 Takeaways: Precision Prevention, Smarter Risk Assessment, and the Evolving Future of Cardiovascular Trials
The P95 Julius Clinical team recently joined researchers, sponsors, clinicians, and industry leaders in Munich for ESC Congress 2026. Across scientific sessions, new clinical guidance, and industry discussions, several themes emerged that could in...
Parkinson’s Is Not One Disease. Why Are We Still Designing Trials as If It Is?
Real-world evidence (RWE) can help neuroscience sponsors account for disease heterogeneity, identify development risks earlier, and build more precise evidence strategies from Day 1.For decades, Parkinson’s disease has often been approached ...
Fact Sheet: Rescue Study Experience
Rescue Study Expertise for At-Risk Clinical Trials When clinical studies face enrollment shortfalls, startup delays, operational challenges, or CRO underperformance, sponsors need more than additional resources. They need an experienced partner c...